Staidson Biopharmaceuticals Hits Day Low Amid Price Pressure, Trading at CNY 24.75

Staidson (Beijing) Biopharmaceuticals Co., Ltd. experienced a notable decline today, with the stock dropping by 4.2% on May 25, 2026. The stock reached an intraday low of CNY 24.75, reflecting ongoing challenges within the company. Over the past week, Staidson's performance has been similarly negative, with a decrease of 4.92%. In the context of broader market performance, the China Shanghai Composite index has shown resilience, gaining 0.51% over the same week. Staidson's year-to-date performance stands at -8.05%, contrasting sharply with the index's positive return of 4.63%. The company has faced significant hurdles, including a reported negative net worth and a low return on capital employed (ROCE) of 0%. Additionally, Staidson has recorded negative results for six consecutive quarters, with net sales declining by 25.81% in the most recent quarter. Despite a strong performance over the past three years, with a 130.46% increase, the current financial metrics indicate a challenging environment for the company moving forward.